Sinphar Pharmaceutical Co. Ltd. - Taiwan
Figures in New Taiwan dollars.
2026 2025
Revenue NT$291,461,000 NT$270,985,000
Jan-Apr Revenue NT$1,117,697,000 NT$1,076,707,000
Source: Taiwan Stock Exchange This content was automatically published based on data and/or text from the original source. For feedback, write to singaporeeditors@dowjones.com.